课题基金 / 基金详情

PROTECTIVE AND THERAPEUTIC IMMUNITY TO PAPILLOMATOSIS

PROTECTIVE AND THERAPEUTIC IMMUNITY TO PAPILLOMATOSIS
对乳头状瘤病的保护性和治疗性免疫
批准号:
3202258
负责人:
JANET L BRANDSMA
金额:
$28.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-07-15 至 1996-04-30

项目摘要

项目成果

JANET L BRANDSMA的其他基金

相似基金

相关文献

中文摘要
翻译
人乳头瘤病毒(HPV)与这种疾病的发生密切相关。 宫颈癌和其他肛门生殖器癌。治疗 癌前病变并不是对所有患者都有效。自发 回归是常见的,但不是普遍的,而且可能在几年内不会发生。 已有报道对许多HPV蛋白具有免疫活性。因此 接种HPV疫苗有望预防癌前病变 发展、诱导或加速它们的退化。疫苗 研发最初不能依赖于临床实验,因为 识别HPV阴性受试者的困难在于 过多的HPV类型,以及癌前病变的复发和 HPV再感染很常见。此外,已经不可能 在感染HPV的动物中诱发疾病。人乳头瘤病毒的最佳动物模型 发展为癌症的疾病是棉尾兔乳头瘤病毒 (CRPV)感染实验兔。我们建议利用CRPV 开发光伏疫苗的模式。初步实验将识别CRPV 编码诱导免疫的蛋白质的基因,这种免疫可以防止 乳头状瘤形成或诱导乳头状瘤消退。后续 实验将评估相应的HPV基因的能力, 在重组CRPV病毒中表达,以诱导保护性或 治疗性免疫。一旦确定了有效的光伏疫苗,他们的 尽可能直接的抗癌疫苗的价值可以使用测试,用于 例如,CRPV或CRPV/HPV诱导的可移植兔癌 以重组体为模型靶点。
英文摘要
Human papillomaviruses (HPVs) are strongly implicated in the development of cervical carcinoma and other anogenital cancers. Treatment of precancerous lesions is not effective in all patients. Spontaneous regression is common but not universal, and may not occur for years. Immune activity to a number of HPV proteins has been reported. Therefore vaccination to HPV holds promise for preventing precancerous lesions from developing or inducing or accelerating their regression. Vaccine development cannot rely initially on clinical experimentation because of the difficulties in identifying HPV-negative subjects because of the plethora of HPV types, and because recurrence of precancerous lesions and HPV reinfection are common. In addition, it has been impossible to induce disease in animals with HPVs. The best animal model for HPV disease that progresses to cancer is cottontail rabbit papillomavirus (CRPV) infection of laboratory rabbits. We propose to utilize the CRPV model to develop PV vaccines. Initial experiments will identify CRPV genes coding for proteins that elicit immunity which protects against papilloma formation or induces papilloma regression. Subsequent experiments will evaluate the ability of corresponding HPV genes, expressed in recombinant CRPV viruses, to elicit protective or therapeutic immunity. Once effective PV vaccines are identified, their value as possible direct anti-cancer vaccines can be tested using, for example, transplantable rabbit carcinomas induced by CRPV or CRPV/HPV recombinants as model targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Langerhans cell-mediated immune modulation of HPV8 expression and tumorgenesis
  • 批准号:
    7530393
  • 项目类别:
  • 资助金额:
    $18.62万
  • 财政年份:
    2008
  • 负责人:
    JANET L BRANDSMA
  • 依托单位:
Langerhans cell-mediated immune modulation of HPV8 expression and tumorgenesis
  • 批准号:
    7624197
  • 项目类别:
  • 资助金额:
    $22.34万
  • 财政年份:
    2008
  • 负责人:
    JANET L BRANDSMA
  • 依托单位:
Papillomavirus E2 as a cervical/anal cancer drug target
  • 批准号:
    6915013
  • 项目类别:
  • 资助金额:
    $24.53万
  • 财政年份:
    2004
  • 负责人:
    JANET L BRANDSMA
  • 依托单位:
Papillomavirus E2 as a cervical/anal cancer drug target
  • 批准号:
    6844396
  • 项目类别:
  • 资助金额:
    $23.39万
  • 财政年份:
    2004
  • 负责人:
    JANET L BRANDSMA
  • 依托单位:
海外基金